BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 23727030)

  • 1. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver.
    Yamada H; Suzuki K; Ichino N; Ando Y; Sawada A; Osakabe K; Sugimoto K; Ohashi K; Teradaira R; Inoue T; Hamajima N; Hashimoto S
    Clin Chim Acta; 2013 Sep; 424():99-103. PubMed ID: 23727030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.
    Salvoza NC; Klinzing DC; Gopez-Cervantes J; Baclig MO
    PLoS One; 2016; 11(4):e0153497. PubMed ID: 27077736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.
    Cermelli S; Ruggieri A; Marrero JA; Ioannou GN; Beretta L
    PLoS One; 2011; 6(8):e23937. PubMed ID: 21886843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease.
    Yamada H; Ohashi K; Suzuki K; Munetsuna E; Ando Y; Yamazaki M; Ishikawa H; Ichino N; Teradaira R; Hashimoto S
    Clin Chim Acta; 2015 Jun; 446():267-71. PubMed ID: 25958847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population.
    Ando Y; Yamazaki M; Yamada H; Munetsuna E; Fujii R; Mizuno G; Ichino N; Osakabe K; Sugimoto K; Ishikawa H; Ohashi K; Teradaira R; Ohta Y; Hamajima N; Hashimoto S; Suzuki K
    Sci Rep; 2019 Dec; 9(1):18856. PubMed ID: 31827150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease.
    Miyaaki H; Ichikawa T; Kamo Y; Taura N; Honda T; Shibata H; Milazzo M; Fornari F; Gramantieri L; Bolondi L; Nakao K
    Liver Int; 2014 Aug; 34(7):e302-7. PubMed ID: 24313922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
    Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
    J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
    Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
    Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease.
    Estep M; Armistead D; Hossain N; Elarainy H; Goodman Z; Baranova A; Chandhoke V; Younossi ZM
    Aliment Pharmacol Ther; 2010 Aug; 32(3):487-97. PubMed ID: 20497147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women.
    Liu PJ; Ma F; Lou HP; Zhu YN; Chen Y
    Climacteric; 2014 Dec; 17(6):692-9. PubMed ID: 24884478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
    Johnson K; Leary PJ; Govaere O; Barter MJ; Charlton SH; Cockell SJ; Tiniakos D; Zatorska M; Bedossa P; Brosnan MJ; Cobbold JF; Ekstedt M; Aithal GP; Clément K; Schattenberg JM; Boursier J; Ratziu V; Bugianesi E; Anstee QM; Daly AK; ;
    JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease.
    Zhang Y; Cheng X; Lu Z; Wang J; Chen H; Fan W; Gao X; Lu D
    Diabetes Res Clin Pract; 2013 Mar; 99(3):327-34. PubMed ID: 23287814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease.
    Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Matono T; Kato J; Tokunaga S; Sugihara T; Hiramatsu A; Hyogo H; Tobita H; Sato S; Kawanaka M; Hara Y; Hino K; Chayama K; Murawaki Y; Isomoto H
    PLoS One; 2020; 15(2):e0219412. PubMed ID: 32106257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of hypoadiponectinemia with non-alcoholic fatty liver disease in urban south Indians--(CURES - 81).
    Gokulakrishnan K; Anjana RM; Indulekha K; Anuradha S; Mohan V
    Indian J Med Res; 2010 Sep; 132():271-7. PubMed ID: 20847373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD.
    Latorre J; Moreno-Navarrete JM; Mercader JM; Sabater M; Rovira Ò; Gironès J; Ricart W; Fernández-Real JM; Ortega FJ
    Int J Obes (Lond); 2017 Apr; 41(4):620-630. PubMed ID: 28119530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet.
    Tryndyak VP; Latendresse JR; Montgomery B; Ross SA; Beland FA; Rusyn I; Pogribny IP
    Toxicol Appl Pharmacol; 2012 Jul; 262(1):52-9. PubMed ID: 22561871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
    Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
    Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
    Hochreuter MY; Dall M; Treebak JT; Barrès R
    Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
    Sun C; Huang F; Liu X; Xiao X; Yang M; Hu G; Liu H; Liao L
    Int J Mol Med; 2015 Mar; 35(3):847-53. PubMed ID: 25605429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulated hepatic microRNAs underlie the association between non-alcoholic fatty liver disease and coronary artery disease.
    Braza-Boïls A; Marí-Alexandre J; Molina P; Arnau MA; Barceló-Molina M; Domingo D; Girbes J; Giner J; Martínez-Dolz L; Zorio E
    Liver Int; 2016 Aug; 36(8):1221-9. PubMed ID: 26901384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.